Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
Pegylated liposomal doxorubicin (PLD) formulation has been approved for the treatment of
recurrent ovarian cancer (ROC). Toxic skin reactions were reported as being the dose-limiting
toxicity and have an impact on patients' quality of life (QoL). The primary aim of this study
was to optimise the toxicity profile by choosing a biweekly schedule of PLD Furthermore, QoL
was investigated. Secondary objective of this study was to evaluate the response rates of
this new regimen.
Phase:
Phase 2
Details
Lead Sponsor:
North Eastern German Society of Gynaecological Oncology North Eastern Germany Society of Gynaecologic Oncology